Arcellx (ACLX) Non-Current Assets (2021 - 2025)
Arcellx (ACLX) recorded quarterly Non-Current Assets of $141.8 million in Q4 2025, down 22.86% quarter-over-quarter from $183.8 million in Q3 2025, and up 26.59% on a YoY basis from $112.0 million in Q4 2024.
Arcellx (ACLX) Non-Current Assets (2021 - 2025) Analysis & Trends
Arcellx's Non-Current Assets history runs 5 years deep, the most recent figure standing at $141.8 million for Q4 2025.
- In Q4 2025, Non-Current Assets rose 26.59% year-over-year to $141.8 million; the TTM figure through Dec 2025 stood at $574.8 million (down 16.06% YoY), while the FY2025 annual figure was $141.8 million, up 26.59% from the prior year.
- Non-Current Assets was $141.8 million for Q4 2025 at Arcellx, down from $183.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $204.1 million in Q2 2024 to a low of $16.0 million in Q4 2021.
- Historically, Non-Current Assets has averaged $105.3 million across 5 years, with a median of $108.8 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets soared 270.25% in 2024, then tumbled 50.81% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $16.0 million in 2021, then soared by 193.96% to $47.0 million in 2022, then jumped by 131.65% to $108.8 million in 2023, then rose by 2.99% to $112.0 million in 2024, then advanced by 26.59% to $141.8 million in 2025.
- The last three Non-Current Assets figures came in at $141.8 million (Q4 2025), $183.8 million (Q3 2025), and $155.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 141.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 141.81 Mn |
| Sep 30, 2025 | 183.84 Mn |
| Jun 30, 2025 | 155.19 Mn |
| Mar 31, 2025 | 93.93 Mn |
| Dec 31, 2024 | 112.02 Mn |
| Sep 30, 2024 | 177.61 Mn |
| Jun 30, 2024 | 204.10 Mn |
| Mar 31, 2024 | 190.96 Mn |
| Dec 31, 2023 | 108.77 Mn |
| Sep 30, 2023 | 122.76 Mn |
| Jun 30, 2023 | 65.46 Mn |
| Mar 31, 2023 | 51.58 Mn |
| Dec 31, 2022 | 46.95 Mn |
| Sep 30, 2022 | 47.02 Mn |
| Jun 30, 2022 | 49.58 Mn |
| Mar 31, 2022 | 22.60 Mn |
| Dec 31, 2021 | 15.97 Mn |